The first, approved non-covalent BTKi, a next-generation oral SERD, a bioactive metabolite of a GHSR1a inverse agonist with the same therapeutic effect but different MOA to its parent are just some of the examples for this month's MOTM. Learn more about the molecules by navigating to the full reviews on the right which cover: why the molecules matter, how they were discovered, the key steps behind optimization, how they work, why the targets were chosen, any interesting toxicology and clinical data, and more. Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Get a free trial to check out substructure search and more features.
Molecules of the Month
January 2023
Molecules of the Month
Molecules of the Month
Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!
Join the Drug Hunter Mailing List
to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.
Popular Content
- 1.2023 Novel Small Molecule FDA Drug Approvals
- 2.Top 12 Most Popular Drug Hunter Case Studies of 2023
- 3.Top Ten Most Popular Drug Hunter Resources of 2023
- 4.Top 10 Most Popular Drug Hunter Review Articles of 2023
- 5.Practical PK Calculators
- 6.AACR Orlando 2023: New Drug Candidates
- 7.PK Cheat Sheet
- 8.Phase I Drug Metabolism
- 9.Why pKas Matter in Medicinal Chemistry and a Drug Discovery Amine pKa Table
- 10.Phase II Drug Metabolism
- 11.First Disclosures from ACS Chicago 2022
- 12.Topliss Tree and Topliss Scheme Posters
VIEW MORE CONTENT